Proprietary AI analyst is now available
- Public Comps
- Henry Schein
Henry Schein Valuation Multiples
Discover Henry Schein's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Addtech, Core & Main, Finning International, Bidcorp Group and more.
Henry Schein Overview
About Henry Schein
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
Founded
1992
HQ

Employees
25.0K
Website
Sectors
Financials (LTM)
EV
$13B
Valuation Multiples
Start free trialHenry Schein Financials
Henry Schein reported last 12-month revenue of $13B and EBITDA of $1B.
In the same LTM period, Henry Schein generated $4B in gross profit, $1B in EBITDA, and $614M in net income.
Revenue (LTM)
Henry Schein P&L
In the most recent fiscal year, Henry Schein reported revenue of $13B and EBITDA of $1B.
Henry Schein is profitable as of last fiscal year, with gross margin of 31%, EBITDA margin of 8%, and net margin of 5%.
Financial data powered by Morningstar, Inc.
Henry Schein Stock Performance
Henry Schein has current market cap of $9B, and enterprise value of $13B.
Market Cap Evolution
Henry Schein's stock price is $81.25.
Henry Schein share price increased by 6.1% in the last 30 days, and by 11.2% in the last year.
Henry Schein has an EPS (earnings per share) of $5.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13B | $9B | -0.0% | 6.1% | 10.2% | 11.2% | $5.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHenry Schein Valuation Multiples
Henry Schein trades at 1.0x EV/Revenue multiple, and 11.4x EV/EBITDA.
EV / Revenue (LTM)
Henry Schein Financial Valuation Multiples
As of June 15, 2026, Henry Schein has market cap of $9B and EV of $13B.
Henry Schein has a P/E ratio of 15.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Henry Schein Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Henry Schein Margins & Growth Rates
Henry Schein grew revenue by 4% and EBITDA by 6% in the last fiscal year.
In the most recent fiscal year, Henry Schein reported gross margin of 31%, EBITDA margin of 8%, and net margin of 5%.
Henry Schein Margins
Henry Schein Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Henry Schein Operational KPIs
Henry Schein's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Henry Schein's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Henry Schein's Rule of X is 19% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Henry Schein Competitors
Henry Schein competitors include Addtech, Core & Main, Finning International, Bidcorp Group, Andritz, Sodexo, Bunzl, Avnet, Indutrade and Pool Corp..
Most Henry Schein public comparables operate across Wholesale Distribution.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 4.1x | 4.0x | 23.0x | 22.5x | |||
| 1.5x | 1.5x | 12.2x | 12.0x | |||
| 1.4x | 1.4x | 11.5x | 11.4x | |||
| 0.7x | 0.7x | 9.9x | 9.6x | |||
| 0.9x | 0.9x | 7.9x | 8.2x | |||
| 0.5x | 0.5x | 7.3x | 8.5x | |||
| 0.9x | 0.9x | 8.7x | 9.0x | |||
| 0.5x | 0.4x | 15.0x | 11.8x | |||
This data is available for Pro users. Sign up to see all Henry Schein competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Henry Schein
Henry Schein has acquired 32 companies to date.
Last acquisition by Henry Schein was on March 3rd 2025. Henry Schein acquired R Weinstein Pharmaceuticals Medical Products for undisclosed valuation.
Latest Acquisitions by Henry Schein
| Description | R Weinstein Pharmaceuticals Medical Products is a distributor of pharmaceuticals, vaccines, medical devices, and supplies headquartered in the U.S. Virgin Islands, maintaining inventory for next-day delivery to healthcare providers in the Caribbean, United States, and Canada. The company stocks over 5,000 SKUs including Pfizer vaccines, BD syringes, and McKesson diagnostics, serving 500 clinics and hospitals annually. Consultants provide product training and compliance support for treatments in oncology, cardiology, and infectious diseases. | Acentus is a UK-based supplier of home-delivered medical equipment and consumables for patients with chronic conditions. It provides oxygen therapy devices, mobility aids, wound care products, and enteral feeding systems via next-day delivery nationwide. The company serves NHS trusts and private care providers from distribution centers in Leeds and Bristol, stocking over 5,000 SKUs tailored for respiratory, diabetes, and palliative care needs. | TriMed is a designer of orthopedic implants and fixation systems for upper and lower extremity fractures. Systems target distal radius, wrist, ulna, clavicle, elbow, forearm, fifth metatarsal, and ankle pathologies using minimally invasive techniques and anatomically contoured plates. | Shield HealthCare is a Valencia, California-headquartered supplier of home medical products encompassing wound dressings, ostomy pouches, incontinence supplies, enteral feeding formulas, urological catheters, and breast pumps. The company ships directly to patients via its e-commerce platform serving the United States. | |
| HQ Country | |||||
| HQ City | Honolulu, HI | Dallas, TX | Los Angeles, CA | - | |
| Deal Date | 3 Mar 2025 | 20 Nov 2024 | 20 Dec 2023 | 3 Aug 2023 | |
| Valuation | undisclosed | undisclosed | $550M | $411M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Henry Schein acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Henry Schein
| When was Henry Schein founded? | Henry Schein was founded in 1992. |
| Where is Henry Schein headquartered? | Henry Schein is headquartered in United States. |
| How many employees does Henry Schein have? | As of today, Henry Schein has over 25K employees. |
| Who is the CEO of Henry Schein? | Henry Schein's CEO is Frederick M. Lowery. |
| Is Henry Schein publicly listed? | Yes, Henry Schein is a public company listed on Nasdaq. |
| What is the stock symbol of Henry Schein? | Henry Schein trades under HSIC ticker. |
| When did Henry Schein go public? | Henry Schein went public in 1995. |
| Who are competitors of Henry Schein? | Henry Schein main competitors include Addtech, Core & Main, Finning International, Bidcorp Group, Andritz, Sodexo, Bunzl, Avnet, Indutrade, Pool Corp.. |
| What is the current market cap of Henry Schein? | Henry Schein's current market cap is $9B. |
| What is the current revenue of Henry Schein? | Henry Schein's last 12 months revenue is $13B. |
| What is the current revenue growth of Henry Schein? | Henry Schein revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Henry Schein? | Current revenue multiple of Henry Schein is 1.0x. |
| What is the current EBITDA of Henry Schein? | Henry Schein's last 12 months EBITDA is $1B. |
| What is Henry Schein's EBITDA margin? | Henry Schein's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Henry Schein? | Current EBITDA multiple of Henry Schein is 11.4x. |
| What is the current FCF of Henry Schein? | Henry Schein's last 12 months FCF is $542M. |
| What is Henry Schein's FCF margin? | Henry Schein's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Henry Schein? | Current FCF multiple of Henry Schein is 23.8x. |
| How many companies Henry Schein has acquired to date? | As of June 2026, Henry Schein has acquired 32 companies. |
| What was the largest acquisition by Henry Schein? | $737M acquisition of Biotech Dental on 16th December 2022 was the largest M&A Henry Schein has done to date. |
| What companies Henry Schein acquired? | Henry Schein acquired Biotech Dental, TriMed, Shield HealthCare, SmartPak Equine, Medivet, Arseus Lab, Arseus Dental Solutions, Logiciel Julie, Arseus, Maravet, and 22 other companies. |
| In how many companies Henry Schein has invested to date? | Henry Schein hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Henry Schein
Lists including Henry Schein
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
